FY26 Appendix 4D and Half Year Report

• Revenue up 15.1% to $8.87 million
• Loss down 72.3% to $7.12 million
• Signed exclusive agreement with IMV Technologies for animal reproduction

Vitrafy Life Sciences Limited reported a 15.1% increase in revenue to $8.87 million and a 72.3% reduction in loss to $7.12 million for the half-year ended 31 December 2025. The company achieved its first major commercial milestone by signing an exclusive, strategic commercial agreement with IMV Technologies to co-develop a market-ready solution for reproductive biological material cryopreservation across farm animals and aquaculture. Under the 12-month agreement, Vitrafy will receive revenue from recurring monthly and milestone payments. Vitrafy also continued to progress its commercial operations in the U.S., with the first Guardion device arriving in California and the establishment of a California office. The company secured an exhibition booth at the upcoming Phacilitate conference in San Diego to showcase its Guardion and LifeChain cryopreservation solution. Vitrafy advanced the commercialization of its cryopreservation platform, completing 4 Guardion unit builds and progressing manufacturing readiness. The company also commenced the medical device clearance process with the U.S. Food and Drug Administration, which is expected to be completed during the first half of FY2027.